You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Metoprolol prevented myocardial infarction but increased risk of stroke and death after non-cardiac surgery

https://doi.org/10.1136/ebm.13.6.175

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    P J Devereaux

    Dr P J Devereaux, McMaster University, Hamilton, Ontario, Canada; phillipj@mcmaster.ca

    STUDY DESIGN

    Design:

    randomised placebo-controlled trial (PeriOperative ISchemic Evaluation [POISE]).

    Allocation concealment:

    concealed.*

    Blinding:

    blinded (patients, clinicians, data collectors, and outcome adjudicators).*

    STUDY QUESTION

    Setting:

    190 hospitals in 23 countries worldwide.

    Patients:

    8351 patients ⩾45 years of age (mean age 69 y, 63% men) who were having non-cardiac surgery with an expected hospital stay ⩾24 hours and fulfilled specific criteria indicating that they had, or were at risk of, atherosclerotic disease.

    Intervention:

    oral extended-release metoprolol succinate (n = 4174) or placebo (n = 4177), 100 mg 2–4 hours before surgery and 6 hours after surgery (or earlier if heart rate was ⩾80 bpm and systolic blood pressure was ⩾100 mm Hg), then 200 mg daily for …

    View Full Text

    Footnotes

    • Source of funding: Canadian Institutes of Health Research; Commonwealth Government of Australia’s National Health and Medical Research Council; Instituto de Salud Carlos III; British Heart Foundation; AstraZeneca.